AXGN

AxoGen, Inc.

Fundamental data last updated:June 12, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Medical - Devices

Exchange

NASDAQ

County of HQ

US

Next Earnings Date

08/04/2026

Business Summary

AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive Soft Tissue Membrane, a processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues in the surgical bed. In addition, the company offers AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. It provides its products to hospitals, surgery centers, and military hospitals plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons in the United States, Canada, Germany, the United Kingdom and other European countries, South Korea, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.

 


VALUATION

P/E

-66.30

Market Cap ($M USD)

$2.15B

Forward P/E

34.25

PEG

0.12

PRICE TO SALES

9.03

PRICE TO BOOK

8.52

EV / EBITDA

366.60

5-Year Average P/E

Free Cash Flow Yield

0.42%

DCF Value

$-22.28

Graham Number

N/A

Price to FCF

240.62

EV to FCF

233.68

Earnings Yield

-1.51%

FCF Yield

0.42%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

-$0.61

Next Year EPS Growth Estimate

$1.18

Next Year Revenue Growth Estimate

$55.46B

Return on Equity (ROE)

-20.74%

FREE CASH FLOW

Operating Margin

-3.79%

Debt-to-Equity

0.15

Piotroski F-Score

6

Altman Z-Score

29.49

Return on Invested Capital (ROIC)

-3.42%

Current Ratio

7.10

Quick Ratio

5.33

Net Debt to EBITDA

-10.89

Interest Coverage

-0.62

Gross Profit margin

75.01%

FCF PER SHARE

$0.17

REVENUE PER SHARE

$4.62

Gainseekers Quantitative Analysis

Summary

AXGN’s valuation is a paradox wrapped in a riddle. With a Forward P/E of 35.64, the market seems to expect a turnaround, yet the negative DCF Value suggests a disconnect between price and intrinsic worth. The Altman Z-score of 30.07 indicates financial stability, but the negative Earnings Yield and ROIC raise red flags about profitability. The stock’s current pricing, extended above its 50-Day SMA, suggests it may be overbought. Investors should tread carefully, as the market appears to be pricing in perfection without the earnings to back it up.

AI Exposure / Tech Reliance

Operating in the Medical Devices industry, AXGN is well-positioned to leverage AI for advancements in surgical precision and patient outcomes. As healthcare increasingly integrates technology, AXGN's focus on nerve repair could benefit from AI-driven innovations. However, the company's adaptability will depend on its ability to integrate these technologies effectively.

The Bull Case

For the optimistic investor, AXGN offers a compelling narrative of potential growth. The Piotroski F-Score of 6 suggests moderate financial health, while a robust Current Ratio of 7.10 indicates strong liquidity. Despite a negative ROIC, the company's low Debt/Equity ratio of 0.15 provides a cushion for strategic investments. The impressive Gross Profit Margin of 75% hints at significant pricing power, making it an intriguing play for those betting on a turnaround.

The Bear Case

Yet, the bear case is equally persuasive. AXGN's Price/Book ratio of 8.86 and Price/Sales of 9.39 are sky-high, signaling overvaluation. The EV to EBITDA multiple of 381.92 is astronomical, suggesting the market is pricing in growth that may not materialize. With a negative EPS and a Price to FCF of 250.38, the company struggles to generate cash flow, raising concerns about its ability to sustain operations without external funding.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$43.43

Institutional Ownership %

1-Year Beta

1.17

Insider Buying % (6 Mo)

Distance to 52-Week High

13.38%

Distance to 52-Week Low

77.19%

EARNINGS SURPRISE %

-41.67%

50-DAY SMA

$37.49

200-DAY SMA

$28.40

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.